Conexiant’s news site is now MDSpire News. Learn more
Advertisement
DOOR framework shows similar outcomes in skin infection trials
“Using DOOR can provide clinicians and patients with a better understanding of the benefits and risks of new anti-infectives being studied to treat skin infections.”
Omadacycline and linezolid showed similar outcomes in a patient-centered analysis of 1,347 participants with acute bacterial skin infections.
2
The DOOR framework ranked outcomes based on survival and three undesirable events, allowing evaluation of treatment benefits and harms together.
3
About 80% of patients in both trials achieved the most desirable DOOR outcome, surviving without any prespecified undesirable events.
4
The probability of a more desirable outcome with omadacycline was 50.6% in OASIS-1 and 52.1% in OASIS-2, indicating no significant treatment differences.
5
The authors recommended future trials to incorporate DOOR and specific health-related quality-of-life instruments for better outcome distinction.
